Skip to main content
CIZZLE BIOTECHNOLOGY HOLDINGS PLC logo

CIZZLE BIOTECHNOLOGY HOLDINGS PLC — Investor Relations & Filings

Ticker · CIZ ISIN · GB00BNG2VN02 LEI · 213800G3OS3SA2J1Y358 IL Professional, scientific and technical activities
Open in API
Filings indexed 305 across all filing types
Latest filing 2022-03-31 Major Shareholding Noti…
Country GB United Kingdom
Listing IL CIZ

About CIZZLE BIOTECHNOLOGY HOLDINGS PLC

https://cizzlebiotechnology.com/

Cizzle Biotechnology Holdings PLC is a cancer diagnostics developer focused on the early detection of lung cancer. The company is advancing a non-invasive, cost-effective blood test designed to identify lung cancer at its earliest stages, often before symptoms appear. The test utilizes a proprietary CIZ1B biomarker and an advanced immunoassay. Its primary goal is to improve patient outcomes by enabling swift, curative medical intervention. The technology aims to streamline the diagnostic pathway, reduce reliance on CT scans which can have high false-positive rates, and eliminate unnecessary invasive follow-up procedures. The company, a spin-out from the University of York, is conducting clinical trials to support global regulatory approval and adoption of its technology.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains fields related to voting rights, shareholder positions, and notification dates, which are characteristic of regulatory filings concerning significant ownership changes. The RNS Number and reference to the Financial Conduct Authority (FCA) confirm its regulatory nature. This specific form (TR-1) is used for Major Shareholding Notifications, which corresponds to the definition for code MRQ.
2022-03-31 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1948 characters) and contains the header 'RNS Number : 6563F'. It announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. This type of immediate, short-form regulatory update, especially one originating from the RNS service and concerning trading mechanics rather than comprehensive financial results or formal reports (like 10-K or IR), fits best under the general 'Regulatory Filings' category, which serves as the fallback for miscellaneous regulatory announcements not covered by more specific codes like DIV, DIRS, or DLST. Since it is a direct announcement of a market event via the RNS system, RNS is the most appropriate classification.
2022-03-22 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1931 characters) and contains specific identifiers like 'RNS Number : 6543F' and mentions 'RNS, the news service of the London Stock Exchange' and the 'Financial Conduct Authority'. The content itself is a brief announcement regarding a 'Price Monitoring Extension' for a security's auction call period. This is a general regulatory announcement that does not fit the specific definitions for financial reports (10-K, IR, ER), management changes (MANG), or shareholder actions (DIV, DVA). Given its nature as a brief, non-standard regulatory notice distributed via the RNS system, the most appropriate classification is the general regulatory fallback category.
2022-03-22 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1948 characters) and contains the header 'RNS Number : 6389F'. It announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates it is a general regulatory announcement disseminated via the RNS system, rather than a specific financial report like an ER, 10-K, or IR. Since it is a general regulatory announcement that doesn't fit the other specific categories (like DIRS, DIV, or MANG), the most appropriate classification is the general Regulatory Filings fallback category.
2022-03-22 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document explicitly starts with 'RNS Number : 6380F' and contains language typical of regulatory news service announcements, including references to the London Stock Exchange and the Financial Conduct Authority (FCA) acting as a Primary Information Provider. The content itself is a brief announcement regarding a 'Price Monitoring Extension' for a security, which is a specific operational update rather than a comprehensive financial report (like 10-K or IR) or a management change (MANG). Given the nature of the announcement being disseminated via the RNS system and its non-financial, operational focus, the most appropriate classification is the general regulatory announcement category, RNS.
2022-03-22 English
Positive outcomes from Arcadia Trial re AZD1656
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 7759D' and concludes with standard boilerplate text referencing 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. This strongly indicates a regulatory news service announcement. The content is an update regarding clinical trial outcomes and commercial discussions related to a drug asset (AZD1656), which is a material event for the company. Since it is a general, timely announcement that doesn't fit perfectly into specific categories like Earnings Release (ER), Director's Dealing (DIRS), or Capital Update (CAP), and it is clearly a regulatory filing distributed via RNS, the most appropriate classification is the general regulatory filing category, RNS.
2022-03-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.